文献速递妇科肿瘤

帕博利珠单抗治疗微卫星高度不稳定晚期子宫内膜癌患者:KEYNOTE-158研究结果

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
PubMed 文献 · J Clin Oncol · 2022-01-06

KEYNOTE-158是一项非随机、开放标签、多队列II期研究,评估帕博利珠单抗200 mg每3周一次、最多35周期治疗经治晚期MSI-H/dMMR子宫内膜癌。79例可评估患者客观缓解率48%(95%CI 37-60),中位缓解持续时间未达到,中位无进展生存期13.1个月,中位总生存期未达到。

要点

  • 经治晚期MSI-H/dMMR子宫内膜癌患者客观缓解率为48%(95%CI 37-60)。
  • 中位缓解持续时间未达到(范围2.9-49.7+个月),中位无进展生存期13.1个月。
  • 76%患者发生至少1例治疗相关不良事件,3-4级占12%,无致死性治疗相关事件。

核心结论

  • 帕博利珠单抗在经治晚期MSI-H/dMMR子宫内膜癌患者中显示出稳健且持久的抗肿瘤活性及令人鼓舞的生存结局,毒性可管理。

研究设计与样本

  • 非随机、开放标签、多队列II期KEYNOTE-158研究(NCT02628067),纳入D队列(子宫内膜癌,不论MSI-H/dMMR状态)和K队列(任何MSI-H/dMMR实体瘤,除外结直肠癌)中经治晚期MSI-H/dMMR子宫内膜癌患者。
  • 患者接受帕博利珠单抗200 mg每3周一次,共35周期。
  • 主要终点为独立中心影像学审阅按RECIST 1.1评估的客观缓解率;次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。
  • 疗效人群为接受至少1剂帕博利珠单抗且随访至少26周的患者,N=79;截至2020年10月5日,90例接受治疗患者中18例(20%)完成35周期,52例(58%)终止治疗。

主要发现

  • 疗效人群中,从首次给药至数据截止的中位时间为42.6个月(范围6.4-56.1个月)。
  • 客观缓解率为48%(95%CI 37-60),中位缓解持续时间未达到(范围2.9-49.7+个月)。
  • 中位无进展生存期为13.1个月(95%CI 4.3-34.4),中位总生存期未达到(95%CI 27.2个月至未达到)。
  • 所有接受治疗患者中,76%发生至少1例治疗相关不良事件(3-4级占12%),无致死性治疗相关事件。
  • 免疫介导不良事件或输液反应发生率为28%(3-4级占7%,无致死性事件)。

关键数值与推荐

  • 客观缓解率48%(95%CI 37-60),依据RECIST 1.1由独立中心影像学审阅评估。
  • 中位缓解持续时间未达到(范围2.9-49.7+个月)。
  • 中位无进展生存期13.1个月(95%CI 4.3-34.4)。
  • 中位总生存期未达到(95%CI 27.2个月至未达到)。
  • 治疗相关不良事件发生率76%,3-4级12%;免疫介导不良事件或输液反应28%,3-4级7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067). We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158. METHODS: Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor, except colorectal) with previously treated, advanced MSI-H/dMMR endometrial cancer received pembrolizumab 200 mg once every 3 weeks for 35 cycles. The primary end point was objective response rate per RECIST version 1.1 by independent central radiologic review. Secondary end points included duration of response, progression-free survival, overall survival, and safety. RESULTS: As of October 5, 2020, 18 of 90 treated patients (20%) had completed 35 cycles of pembrolizumab and 52 (58%) had discontinued treatment. In the efficacy population (patients who received ≥ 1 dose of pembrolizumab and had ≥ 26 weeks of follow-up; N = 79), the median time from first dose to data cutoff was 42.6 (range, 6.4-56.1) months. The objective response rate was 48% (95% CI, 37 to 60), and median duration of response was not reached (2.9-49.7+ months). Median progression-free survival was 13.1 (95% CI, 4.3 to 34.4) months, and median overall survival was not reached (95% CI, 27.2 months to not reached). Among all treated patients, 76% had ≥ 1 treatment-related adverse event (grades 3-4, 12%). There were no fatal treatment-related events. Immune-mediated adverse events or infusion reactions occurred in 28% of patients (grades 3-4, 7%; no fatal events). CONCLUSION: Pembrolizumab demonstrated robust and durable antitumor activity and encouraging survival outcomes with manageable toxicity in patients with previously treated, advanced MSI-H/dMMR endometrial cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022. PMID: 34990208. doi:10.1200/JCO.21.01874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。